News of Note—Sanofi, GlaxoSmithKline's 2017 vaccine sales and more

Here is some other vaccine news of note for the week:

> Sanofi delivered vaccine sales growth of 8.3% to $6.29 billion for 2017, driven primarily by travel and other endemics vaccines. Release

> GlaxoSmithKline's vaccine sales grew 6% last year to $7.24 billion. Release

> Médecins Sans Frontières is taking a patent battle against Pfizer's Prevnar 13 to the Supreme Court of South Korea. Release

> The CDC has released new recommended immunization schedules for adults and children. Changes include recommending GlaxoSmithKline’s recombinant zoster vaccine Shingrix over Merck & Co.’s Zostavax for adults 50 or older. Children advisory | Adult advisory 

> U.S. Sen. Edward Markey, D-Mass., is calling on the country to spend $1 billion to develop a universal flu vaccine. Associated Press article

> Vaxart said its oral flu vaccine significantly reduced influenza infections compared with an approved quadrivalent influenza vaccine in a phase 2 challenge study. Release